Extended Data Fig. 1: ORR and PFS according to HER3-membrane expression.
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
a. ORR and PFS according to HER3 membrane positivity as measured by overall membrane positivity at 10x and scored as < 25%, 25-75% and > 75% of tumor cells; b. ORR and PFS according to HER3 membrane positivity as measured by H-score 0-100, 100-200, ≥ 200; the 95% confidence interval was estimated using the Clopper–Pearson exact method.
